Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, recent research has raised concerns about the safety of Dupixent. Studies suggest the drug may increase the risk of cutaneous T-cell lymphoma (CTCL), a rare but aggressive cancer that affects the immune system and often first appears on the skin. Multiple studies report that patients taking Dupixent may be three to four times more likely to develop CTCL than those not using the drug.
Early CTCL can look like eczema, and because Dupixent reduces inflammation, it may temporarily hide the signs of lymphoma, delaying diagnosis until the disease becomes more advanced. Researchers have documented patients who started Dupixent for eczema and were later diagnosed with CTCL, with some reports suggesting that Dupixent may have accelerated the progression of the disease. While Dupixent continues to help many patients, this growing body of evidence has prompted doctors, regulators, and patients to carefully evaluate the risks.
Patients and families are filing lawsuits against Dupixent’s manufacturers, claiming the companies failed to adequately warn about the risk of lymphoma, that Dupixent may have delayed or masked the diagnosis of CTCL, making treatment more difficult, and that patients suffered serious health consequences as a result. If you or a loved one took Dupixent and notice persistent or unusual rashes, patches or plaques on the skin that don’t heal, enlarged lymph nodes, or a diagnosis of CTCL, it may be linked to Dupixent use, and medical advice should be sought promptly.
Those affected by Dupixent-related lymphoma may be entitled to recover compensation for medical expenses, lost wages, pain, suffering, and emotional harm. If you or someone you love was diagnosed with lymphoma after using Dupixent, don’t wait, as lawsuits are already underway nationwide and strict time limits apply.
"Patients deserve to know the full risks of any medication they take. At Robert Peirce & Associates, we are committed to holding pharmaceutical companies accountable and ensuring those harmed by Dupixent have access to justice and the compensation they deserve," Aaron Rihn, Attorney at Robert Peirce & Associates.
Contact Robert Peirce & Associates for a free, confidential case evaluation by calling Aaron Rihn at 412-281-7229 or visiting www.peircelaw.com. For over 40 years, Robert Peirce & Associates has provided diligent and compassionate legal representation to individuals harmed by negligent pharmaceutical companies. You pay nothing unless the firm wins your case.